arkoleo's library 27 articles Export Sort

Hide details

	1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. [My Copy] Journal of medicinal chemistry, Vol. 52, No. 13. (9 July 2009), pp. 3954-3968. by Karen Miller-Moslin, Stefan Peukert, Rishi K. Jain, et al.Michael A. McEwan, Rajesh Karki, Luis Llamas, Naeem Yusuff, Feng He, Yanhong Li, Yingchuan Sun, Miao Dai, Lawrence Perez, Walter Michael, Tao Sheng, Huangshu Lei, Rui Zhang, Juliet Williams, Aaron Bourret, Arun Ramamurthy, Jing Yuan, Ribo Guo, Melissa Matsumoto, Anthony Vattay, Wieslawa Maniara, Adam Amaral, Marion Dorsch, Joseph F. Kelleher posted to no-tag by arkoleo on 2009-09-04 13:33:44 as
	Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). [My Copy] Journal of medicinal chemistry, Vol. 52, No. 14. (23 July 2009), pp. 4400-4418. by Martin R. Tremblay, André Lescarbeau, Michael J. Grogan, et al.Eddy Tan, Grace Lin, Brian C. Austad, Lin-Chen C. Yu, Mark L. Behnke, Somarajan J. Nair, Margit Hagel, Kerry White, James Conley, Joseph D. Manna, Teresa M. Alvarez-Diez, Jennifer Hoyt, Caroline N. Woodward, Jens R. Sydor, Melissa Pink, John MacDougall, Matthew J. Campbell, Jill Cushing, Jeanne Ferguson, Michael S. Curtis, Karen McGovern, Margaret A. Read, Vito J. Palombella, Julian Adams, Alfredo C. Castro posted to no-tag by arkoleo on 2009-09-04 13:29:15 as
	Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. [My Copy] Investigational new drugs, Vol. 26, No. 4. (August 2008), pp. 355-362. by Sharon L. Sanborn, Matthew M. Cooney, Afshin Dowlati, et al.Joanna M. Brell, Smitha Krishnamurthi, Joseph Gibbons, Joseph A. Bokar, Charles Nock, Anne Ness, Scot C. Remick posted to no-tag by arkoleo on 2009-08-11 13:23:30 as
	ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 13, No. 9. (1 May 2007), pp. 2728-2737. by Cherrie K. Donawho, Yan Luo, Yanping Luo, et al.Thomas D. Penning, Joy L. Bauch, Jennifer J. Bouska, Velitchka D. Bontcheva-Diaz, Bryan F. Cox, Theodore L. DeWeese, Larry E. Dillehay, Debra C. Ferguson, Nayereh S. Ghoreishi-Haack, David R. Grimm, Ran Guan, Edward K. Han, Rhonda R. Holley-Shanks, Boris Hristov, Kenneth B. Idler, Ken Jarvis, Eric F. Johnson, Lawrence R. Kleinberg, Vered Klinghofer, Loren M. Lasko, Xuesong Liu, Kennan C. Marsh, Thomas P. McGonigal, Jonathan A. Meulbroek, Amanda M. Olson, Joann P. Palma, Luis E. Rodriguez, Yan Shi, Jason A. Stavropoulos, Alan C. Tsurutani, Gui-Dong D. Zhu, Saul H. Rosenberg, Vincent L. Giranda, David J. Frost posted to no-tag by arkoleo on 2009-08-11 12:55:45 as
	A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. [My Copy] Neuro-oncology, Vol. 5, No. 2. (April 2003), pp. 79-88. by Manfred Westphal, Dana C. Hilt, Enoch Bortey, et al.Patrick Delavault, Robert Olivares, Peter C. Warnke, Ian R. Whittle, Juha Jääskeläinen, Zvi Ram posted to no-tag by arkoleo on 2009-08-11 12:44:21 as
	Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 25, No. 13. (1 May 2007), pp. 1651-1657. by L. Burt Nabors, Tom Mikkelsen, Steven S. Rosenfeld, et al.Fred Hochberg, Narasimha S. Akella, Joy D. Fisher, Gretchen A. Cloud, Yu Zhang, Kathryn Carson, Sabine M. Wittemer, A. Dimitrios Colevas, Stuart A. Grossman posted to no-tag by arkoleo on 2009-08-10 15:17:59 as along with 1 person paulschlesinger
	Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. [My Copy] Cancer chemotherapy and pharmacology, Vol. 61, No. 6. (May 2008), pp. 911-921. by Henriette Gourdeau, James B. McAlpine, Maxime Ranger, et al.Bryan Simard, Francois Berger, Francis Beaudry, Chris M. Farnet, Pierre Falardeau posted to no-tag by arkoleo on 2009-08-10 00:23:00 as
	Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. [My Copy] Anti-cancer drugs, Vol. 16, No. 9. (October 2005), pp. 917-921. by Christoph A. Jacobi, Charalambos Menenakos, Chris Braumann posted to no-tag by arkoleo on 2009-08-09 23:56:09 as
	Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. [My Copy] British journal of cancer, Vol. 80, No. 5-6. (May 1999), pp. 756-765. by T. Glaser, S. Winter, P. Groscurth, et al.H. Safayhi, E. R. Sailer, H. P. Ammon, M. Schabet, M. Weller posted to no-tag by arkoleo on 2009-08-09 22:08:52 as
	Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. [My Copy] Cytokine & growth factor reviews, Vol. 17, No. 1-2. (r 2006), pp. 129-139. by Karl-Hermann H. Schlingensiepen, Reimar Schlingensiepen, Andreas Steinbrecher, et al.Peter Hau, Ulrich Bogdahn, Birgit Fischer-Blass, Piotr Jachimczak posted to no-tag by arkoleo on 2009-08-09 21:33:47 as
	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. [My Copy] Investigational new drugs, Vol. 23, No. 5. (October 2005), pp. 495-503. by Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, et al.Joel M. Reid, Mary J. Kuffel, Matthew M. Ames, Bernd W. Scheithauer, Julie E. Hammack, George Pipoly, Steven A. Kuross posted to no-tag by arkoleo on 2009-08-07 14:33:04 as
	Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. [My Copy] Journal of the National Cancer Institute, Vol. 99, No. 18. (19 September 2007), pp. 1410-1414. by Hong Jiang, Candelaria Gomez-Manzano, Hiroshi Aoki, et al.Marta M. Alonso, Seiji Kondo, Frank McCormick, Jing Xu, Yasuko Kondo, B. Nebiyou Bekele, Howard Colman, Frederick F. Lang, Juan Fueyo posted to no-tag by arkoleo on 2009-08-06 15:57:02 as
	Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 20, No. 5. (1 March 2002), pp. 1389-1397. by David A. Reardon, Gamal Akabani, R. Edward Coleman, et al.Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, Lorna V. Regalado, John H. Sampson, Timothy D. Shafman, Carol J. Wikstrand, Terence Z. Wong, Xiao-Guang G. Zhao, Michael R. Zalutsky, Darell D. Bigner posted to no-tag by arkoleo on 2009-08-06 15:50:26 as
	Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. [My Copy] Integrative cancer therapies, Vol. 5, No. 1. (March 2006), pp. 40-47. by Stanislaw R. Burzynski, Tomasz J. Janicki, Robert A. Weaver, Barbara Burzynski posted to no-tag by arkoleo on 2009-08-06 14:17:17 as
	Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. [My Copy] Cancer research, Vol. 68, No. 1. (1 January 2008), pp. 266-275. by Eun Hee H. Kim, Mi Jin J. Yoon, Seung U. Kim, Taeg Kyu K. Kwon, Seonghyang Sohn, Kyeong Sook S. Choi posted to no-tag by arkoleo on 2009-08-06 13:47:23 as
	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, No. 21. (1 November 2005), pp. 7841-7850. by Andrew B. Lassman, Michael R. Rossi, Jeffrey J. Raizer, et al.Jeffrey R. Razier, Lauren E. Abrey, Frank S. Lieberman, Chelsea N. Grefe, Kathleen Lamborn, William Pao, Alan H. Shih, John G. Kuhn, Richard Wilson, Norma J. Nowak, John K. Cowell, Lisa M. DeAngelis, Patrick Wen, Mark R. Gilbert, Susan Chang, W. A. Yung, Michael Prados, Eric C. Holland posted to no-tag by arkoleo on 2009-08-05 20:13:49 as
	Effect of trans sodium crocetinate on brain tumor oxgenation. [My Copy] Journal of neurosurgery, Vol. 111, No. 2. (August 2009), pp. 226-229. by Jason Sheehan, Jonathan Sherman, Christopher Cifarelli, et al.Jay Jagannathan, Kasandra Dassoulas, Claire Olson, Jessica Rainey, Shaojie Han posted to no-tag by arkoleo on 2009-08-05 19:59:18 as
	Immunotherapeutic approaches for glioma. [My Copy] Critical reviews in immunology, Vol. 29, No. 1. (2009), pp. 1-42. by Hideho Okada, Gary Kohanbash, Xinmei Zhu, et al.Edward R. Kastenhuber, Aki Hoji, Ryo Ueda, Mitsugu Fujita posted to no-tag by arkoleo on 2009-08-04 15:46:53 as
	Gene therapeutics: the future of brain tumor therapy? [My Copy] Expert review of anticancer therapy, Vol. 6, No. 7. (July 2006), pp. 1053-1064. by Jennifer L. Cutter, Kazuhiko Kurozumi, E. Antonio Chiocca, Balveen Kaur posted to review by arkoleo on 2009-08-04 15:41:23 as
	Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. [My Copy] The Journal of biological chemistry, Vol. 281, No. 16. (21 April 2006), pp. 10691-10697. by Seyed Isaac I. Hashemy, Johanna S. Ungerstedt, Farnaz Zahedi Avval, Arne Holmgren posted to gadolinium motexafin by arkoleo on 2009-08-04 14:54:43 as
	Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, No. 5. (10 February 2009), pp. 740-745. by Teri N. Kreisl, Lyndon Kim, Kraig Moore, et al.Paul Duic, Cheryl Royce, Irene Stroud, Nancy Garren, Megan Mackey, John A. Butman, Kevin Camphausen, John Park, Paul S. Albert, Howard A. Fine posted to bevacizumab irinotecan by arkoleo on 2009-08-04 14:25:21 as
	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. [My Copy] Neuro-oncology, Vol. 8, No. 2. (April 2006), pp. 189-193. by Michael D. Prados, Kathleen Lamborn, W. K. Yung, et al.Kurt Jaeckle, H. Ian Robins, Minesh Mehta, Howard A. Fine, Patrick Y. Wen, Timothy Cloughesy, Susan Chang, M. Kelly Nicholas, David Schiff, Harry Greenberg, Larry Junck, Karen Fink, Ken Hess, John Kuhn, North American Brain Tumor Consortium posted to irinotechan by arkoleo on 2009-08-04 14:12:44 as
	A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. [My Copy] Cancer, Vol. 110, No. 11. (1 December 2007), pp. 2535-2541. by Maryam Fouladi, H. Stacy Nicholson, Tianni Zhou, et al.Fred Laningham, Kathleen J. Helton, Emi Holmes, Kenneth Cohen, Rose Anne A. Speights, John Wright, Ian F. Pollack, Children's Oncology Group posted to no-tag by arkoleo on 2009-08-04 14:02:59 as
	AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 13, No. 22 Pt 1. (15 November 2007), pp. 6735-6742. by H. Toni Jun, Jan Sun, Karen Rex, et al.Robert Radinsky, Richard Kendall, Angela Coxon, Teresa L. Burgess posted to no-tag by arkoleo on 2009-08-04 14:00:28 as
	Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. [My Copy] Glia, Vol. 39, No. 2. (August 2002), pp. 162-173. by Susan A. Lyons, Jeffrey O'Neal, Harald Sontheimer posted to no-tag by arkoleo on 2009-08-03 15:17:43 as
	Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). [My Copy] Expert opinion on drug delivery, Vol. 4, No. 2. (March 2007), pp. 175-186. by Adam N. Mamelak, Douglas B. Jacoby posted to tm-601 by arkoleo on 2009-08-03 15:14:26 as
	A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. [My Copy] Cancer cell, Vol. 11, No. 1. (January 2007), pp. 37-51. by Sébastien Bonnet, Stephen L. Archer, Joan Allalunis-Turner, et al.Alois Haromy, Christian Beaulieu, Richard Thompson, Christopher T. Lee, Gary D. Lopaschuk, Lakshmi Puttagunta, Sandra Bonnet, Gwyneth Harry, Kyoko Hashimoto, Christopher J. Porter, Miguel A. Andrade, Bernard Thebaud, Evangelos D. Michelakis posted to no-tag by arkoleo on 2009-08-03 14:06:22 as along with 5 people and 3 groups tonamswish cito eyliu naturecure PeterDAdamo Boydian_Society Nutritional_Polymorphisms The_Individualist

Note: You may cite this page as: http://www.citeulike.org/user/arkoleo

gadolinium	1
tm-601	1
motexafin	1
review	1
irinotechan	1
irinotecan	1
bevacizumab	1

arkoleo's library 27 articles Export Sort

arkoleo's tags